賽生藥業(06600.HK):建議市場上股份購回計劃
格隆匯3月25日丨賽生藥業(06600.HK)發佈公吿,董事會已批准行使股份購回授權的計劃,而該授權已於2021年6月16日舉行的股東周年大會上由公司股東授予董事會,以於適當時候從公開市場購回股份。根據股份購回授權,公司獲許購回最多6778.74萬股,佔公司於股東周年大會當日於聯交所已發行股份總數的10%。為根據上市規則的規定維持足夠公眾持股量,董事會於進行建議股份購回計劃時不會悉數行使股份購回授權。建議股份購回計劃的批准期限不會超過該公吿日期起計三個月。
董事會認為,股份現時的成交價未能反映其內在價值及公司實際業務前景。董事會相信,建議股份購回計劃及於其後註銷所購回的股份可提升股份的價值,從而提高公司股東的回報。董事會認為建議股份購回計劃符合公司及其股東整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.